trial

The Sub-Sero Study

NCTId NCT03994965
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Withdrawn
Enrollment 0 (actual)
Sponsored by Bjorn H. Ebdrup
Primary completion 2024-12-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2024-12-01
Primary completion
2024-12-02
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
Pimavanserin

Sponsors

Bjorn H. EbdrupLead Sponsor
Rigshospitalet, DenmarkCollaborator
University of CopenhagenCollaborator
ACADIA Pharmaceuticals Inc.Collaborator

Investigators

1
Bjørn H Ebdrup, MD, PhDPrincipal Investigator

Sites

0 total

Linked catalysts

1
The Sub-Sero Study — primary completion2024-12-02

Facts & assertions

4 sourced
Enrollment
0
Phase
PHASE2
Primary Completion Date
2024-12-02
Status
WITHDRAWN
relationships
The graph out of here
drug
Pimavanserin
drug
lead_sponsor
Bjorn H. Ebdrup
company
collaborator
Rigshospitalet, Denmark
company
University of Copenhagen
company
indication
Schizophrenia
indication
Psychosis
indication
Schizophrenia
indication
investigator
Bjørn H Ebdrup, MD, PhD
person